Organometallic compound and organic light-emitting device including the same

Description

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to and the benefit of Korean Patent Application No. 10-2014-0182552, filed on Dec. 17, 2014, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by reference.

BACKGROUND

1. Field

The present disclosure relates to an organometallic compound and an organic light-emitting device including the same.

2. Description of the Related Art

Organic light-emitting devices (OLEDs) are self-emission devices that have wide viewing angles, high contrast ratios, and short response times. In addition, the OLEDs exhibit excellent luminance, driving voltage, and response speed characteristics, and produce full-color images.

A typical organic light-emitting device includes an anode, a cathode, and an organic layer that is disposed between the anode and the cathode and includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and electrons recombine in an emission layer and generate excitons. These excitons change from an excited state to a ground state to thereby generate light.

Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.

SUMMARY

Provided are an organometallic compound and an organic light-emitting device including the organometallic compound.

Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented exemplary embodiments.

According to an aspect of an exemplary embodiment, an organometallic compound is represented by Formula 1:

M(L₁)_n1(L₂)_n2 Formula 1

embedded image

wherein in Formula 1,

M is selected from Ir, Pt, Os, Ti, Zr, Hf, Eu, Tb, Tm, and Rh,

L₁in Formula 1 is selected from ligands represented by Formula 2A,

L₂in Formula 1 is selected from ligands represented by Formula 2B,

provided that L₁and L₂in Formula 1 are different from each other,

n1 and n2 in Formula 1 are each independently 1 or 2, and the sum of n1 and n2 is 2 or 3,

Y₁and Y₂in Formula 2A are each independently C or N, and Y₃and Y₄in Formula 2B are each independently C or N,

in Formulae 2A and 2B,

CY₁and CY₃are each independently a C₁-C₆₀heterocyclic group,

CY₂and CY₄are each independently selected from a C₅-C₆₀carbocyclic group and a C₁-C₆₀heterocyclic group,

wherein CY₁and CY₂are optionally linked to each other through a first linking group, and, CY₃and CY₄are optionally linked to each other through a second linking group,

in Formulae 2A and 2B, Z₁to Z₄are each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀alkyl group, a substituted or unsubstituted C₂-C₆₀alkenyl group, a substituted or unsubstituted C₂-C₆₀alkynyl group, a substituted or unsubstituted C₁-C₆₀alkoxy group, a substituted or unsubstituted C₃-C₁₀cycloalkyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀aryl group, a substituted or unsubstituted C₆-C₆₀aryloxy group, a substituted or unsubstituted C₆-C₆₀arylthio group, a substituted or unsubstituted C₁-C₆₀heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉),

a1 to a4 are each independently an integer selected from 0 to 4,

in Formula 2B, R₁₁and R₁₂are each independently selected from groups represented by Formula 2C,

b1 and b2 are each independently an integer selected from 0 to 3, and the sum of b1 and b2 is 1 or greater,

in Formula 2C, R₁to R₃are each independently selected from a substituted or unsubstituted C₁-C₆₀alkyl group, a substituted or unsubstituted C₂-C₆₀alkenyl group, a substituted or unsubstituted C₂-C₆₀alkynyl group, a substituted or unsubstituted C₁-C₆₀alkoxy group, a substituted or unsubstituted C₃-C₁₀cycloalkyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀aryl group, a substituted or unsubstituted C₆-C₆₀aryloxy group, a substituted or unsubstituted C₆-C₆₀arylthio group, a substituted or unsubstituted C₁-C₆₀heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,

when b1 is 1 or greater, at least one of R₁to R₃in Formula 2C is optionally bound to neighboring group Z₃to form a saturated or unsaturated ring having two to ten carbons,

when b2 is 1 or greater, at least one of R₁to R₃in Formula 2C is optionally bound to neighboring group Z₄to form a saturated or unsaturated ring having two to ten carbons,

* and *′ in Formulae 2A and 2B are a binding site to M in Formula 1, and * in Formula 2C is a binding site to CY₃or CY₄in Formula 2B,

at least one of substituents of the substituted C₁-C₆₀alkyl group, substituted C₂-C₆₀alkenyl group, substituted C₂-C₆₀alkynyl group, substituted C₁-C₆₀alkoxy group, substituted C₃-C₁₀cycloalkyl group, substituted C₁-C₁₀heterocycloalkyl group, substituted C₃-C₁₀cycloalkenyl group, substituted C₁-C₁₀heterocycloalkenyl group, substituted C₆-C₆₀aryl group, substituted C₆-C₆₀aryloxy group, substituted C₆-C₆₀arylthio group, substituted C₁-C₆₀heteroaryl group, substituted monovalent non-aromatic condensed polycyclic group, and substituted monovalent non-aromatic condensed heteropolycyclic group is selected from

a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀alkyl group, a C₂-C₆₀alkenyl group, a C₂-C₆₀alkynyl group, and a C₁-C₆₀alkoxy group;

a C₁-C₆₀alkyl group, a C₂-C₆₀alkenyl group, a C₂-C₆₀alkynyl group, and a C₁-C₆₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₆₀aryl group, a C₆-C₆₀aryloxy group, a C₆-C₆₀arylthio group, a C₁-C₆₀heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(═O)(Q₁₈)(Q₁₉);

a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₆₀aryl group, a C₆-C₆₀aryloxy group, a C₆-C₆₀arylthio group, a C₁-C₆₀heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀alkyl group, a C₂-C₆₀alkenyl group, a C₂-C₆₀alkynyl group, a C₁-C₆₀alkoxy group, a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₆₀aryl group, a C₆-C₆₀aryloxy group, a C₆-C₆₀arylthio group, a C₁-C₆₀heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(═O)(Q_2a)(Q₂₉), and

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(═O)(Q₃₈)(Q₃₉),

According to an aspect of another exemplary embodiment, an organic light-emitting device includes:

a first electrode;

a second electrode; and

an organic layer disposed between the first electrode and the second electrode,

wherein the organic layer includes an emission layer, and

wherein the organic layer includes at least one organometallic compound represented by Formula 1.

The organometallic compound may be included in the emission layer, the emission layer may further include a host, and an amount of the organometallic compound may be less than an amount of the host.

BRIEF DESCRIPTION OF THE DRAWINGS

These and/or other aspects will become apparent and more readily appreciated from the following description of the exemplary embodiments, taken in conjunction with the accompanying drawings in which:

FIG. 1 is a schematic cross-sectional view of an organic light-emitting device according to an embodiment.

DETAILED DESCRIPTION

Reference will now be made in detail to exemplary embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present exemplary embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the exemplary embodiments are merely described below, by referring to the figures, to explain aspects. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.

Spatially relative terms, such as “beneath,” “below,” “lower,” “above,” “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below” or “beneath” other elements or features would then be oriented “above” the other elements or features. Thus, the exemplary term “below” can encompass both an orientation of above and below. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.

About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within ±30%, 20%, 10%, 5% of the stated value.

Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

An organometallic compound represented by Formula 1 below is provided:

M(L₁)_n1(L₂)_n2 Formula 1

In Formula 1,

L₁is selected from ligands that are each represented by Formula 2A, and

L₂is selected from ligands that are each represented by Formula 2B:

embedded image

In Formulae 2A and 2B, * and *′ are each a binding site to M in Formula 1.

In Formula 1, M may be selected from iridium (Ir), platinum (Pt), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), thulium (Tm), and rhodium (Rh).

For example, in Formula 1, M may be Ir or Pt.

In Formula 1, L₁and L₂are different from each other, n1 and n2 are each independently 1 or 2, and the sum of n1 and n2 is 2 or 3.

In Formula 2A, Y₁and Y₂may be each independently carbon (C) or nitrogen (N), and, in Formula 2B, Y₃and Y₄may be each independently C or N.

For example, in Formula 2A, Y₁to Y₄may be C, but embodiments are not limited thereto.

In Formulae 2A and 2B, CY₁and CY₃may be each independently a C₁-C₆₀heterocyclic group; CY₂and CY₄may be each independently selected from a C₅-C₆₀carbocyclic group and a C₁-C₆₀heterocyclic group; CY₁and CY₂may be optionally bound to each other through a first linking group; and, CY₃and CY₄may be optionally bound to each other through a second linking group. The C₅-C₆₀carbocyclic group and C₁-C₆₀heterocyclic group may be “a monocyclic group” or “a polycyclic group”.

In an embodiment, in Formulae 2A and 2B, CY₁and CY₃may be each independently selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a quinoline ring, an isoquinoline ring, a quinazoline ring, a quinoxaline ring, a triazole ring, an imidazole ring, and a pyrazole ring; and CY₂and CY₄may be each independently selected from a benzene ring, a naphthalene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a quinoline ring, an isoquinoline ring, a quinazoline ring, a quinoxaline ring, a carbazole ring, a dibenzofuran ring, and a dibenzothiophene ring.

In another embodiment, in Formulae 2A and 2B, CY₁and CY₃may be each independently selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a triazole ring, an imidazole ring, and a pyrazole ring; and CY₂and CY₄may be each independently selected from a benzene ring, a naphthalene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a carbazole ring, a dibenzofuran ring, and a dibenzothiophene ring.

In some embodiments, in Formulae 2A and 2B, CY₁and CY₃may be each independently selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, and a triazine ring; and CY₂and CY₄may be each independently selected from a benzene ring, a naphthalene ring, a carbazole ring, a dibenzofuran ring, and a dibenzothiophene ring, but embodiments are not limited thereto.

In Formula 2A, CY₁and CY₂may be optionally bound to each other through the first linking group; and, in Formula 2B, CY₃and CY₄may be optionally bound to each other through the second linking group. The first linking group and the second linking group may be each independently selected from liking groups represented by Formula 6:

*—(Z₃₁)_b10—*′ Formula 6

In Formula 6, wherein Z₃₁is selected from *—O—*′, *—S—*′, *—N(Q₄₁)-*, *—C(Q₄₂)(Q₄₃)-*′, *—C(Q₄₄)=C(Q₄₅)-*′, and

embedded image

Q₄₁to Q₄₉are each independently selected from

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group; and

a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

b10 is an integer selected from 1 to 10, and when b10 is 2 or greater, groups Z₃₁are identical to or different from each other.

For example, in Formula 6, Q₄₁to Q₄₉are each independently selected from

a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group, but embodiments are not limited therefrom.

For example, in Formula 2A, CY₁and CY₂are optionally bound to each other through the first linking group, and/or, in Formula 2B, CY₃and CY₄are optionally bound to each other through the second linking group, wherein the first linking group and the second linking group are each independently represented by *—C(Q₄₄)=C(Q₄₅)-*′ or

embedded image

(i.e., b10=1 in Formula 6), wherein Q₄₄to Q₄₉are each independently selected from a hydrogen, a C₁-C₁₀alkyl group, and a C₁-C₁₀alkoxy group, embodiments are not limited thereto.

In Formulae 2A and 2B, Z₁to Z₄may be each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀alkyl group, a substituted or unsubstituted C₂-C₆₀alkenyl group, a substituted or unsubstituted C₂-C₆₀alkynyl group, a substituted or unsubstituted C₁-C₆₀alkoxy group, a substituted or unsubstituted C₃-C₁₀cycloalkyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀aryl group, a substituted or unsubstituted C₆-C₆₀aryloxy group, a substituted or unsubstituted C₆-C₆₀arylthio group, a substituted or unsubstituted C₁-C₆₀heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉).

In an embodiment, in Formulae 2A and 2B, Z₁to Z₄are each independently

a hydrogen, a deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀alkyl group, and a C₁-C₂₀alkoxy group;

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀alkyl group, a C₁-C₁₀alkoxy group, a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₁₄aryl group, a C₁-C₁₄heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₁₄aryl group, a C₁-C₁₄heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀alkyl group, a C₁-C₂₀alkoxy group, a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₁₄aryl group, a C₁-C₁₄heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group; and

—N(Q₁)(Q₂), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉),

wherein Q₁, Q₂and Q₆to Q₉may be each independently selected from a C₁-C₂₀alkyl group, a C₁-C₂₀alkoxy group, a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₁₄aryl group, a C₆-C₁₄aryl group substituted with at least one of a C₁-C₂₀alkyl group and a C₆-C₁₄aryl group, a C₁-C₁₄heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

In another embodiment, in Formulae 2A and 2B, Z₁to Z₄may be each independently selected from

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl (adamantyl) group, a norbornanyl (norbornyl) group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀alkyl group, a C₁-C₂₀alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group; and

—B(Q₆)(Q₇) and —P(═O)(Q₈)(Q₉),

wherein Q₆to Q₉are each independently selected from

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCD₂H, —CHDCDH₂, —CHDCD₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one of a deuterium, a C₁-C₁₀alkyl group, and a phenyl group, embodiments are not limited thereto.

In some embodiments, in Formulae 2A and 2B, Z₁to Z₄are each independently selected from

a hydrogen, a deuterium, —F, a cyano group, a nitro group, —SF₅, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a cyano group, a nitro group, a C₁-C₁₀alkyl group, a C₁-C₁₀alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group; and

—B(Q₆)(Q₇) and —P(═O)(Q₈)(Q₉),

wherein Q₆to Q₉are each independently selected from

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from a deuterium, a C₁-C₁₀alkyl group, and a phenyl group.

In some embodiments, in Formulae 2A and 2B, Z₁to Z₄may be each independently selected from a hydrogen, a deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a group represented by Formulae 9-1 to 9-17, and a group represented by Formulae 10-1 to 10-32:

embedded image

In Formulae 2A and 2B, a1 to a4 may be each independently an integer selected from 0 to 4. When a1 is 2 or greater, groups Z₁may be identical to or different from each other; when a2 is 2 or greater, groups Z₂may be identical to or different from each other; when a3 is 2 or greater, groups Z₃may be identical to or different from each other; and when a4 is 2 or greater, groups Z₄may be identical to or different from each other.

In Formula 2B, R₁₁and R₁₂are each independently a group represented by Formula 2C, b1 and b2 are each independently an integer selected from 0 to 3, and the sum of b1 and b2 is 1 or greater. That is, the ligand represented by Formula 2B includes at least one of groups represented by Formula 2C as a substituent.

In an embodiment, in Formula 2B, b1 may be 1 or 2, and b2 may be 0.

In another embodiment, in Formula 2B, b1 may be 1, and b2 may be 1.

In another embodiment, in Formula 2B, b1 may be 1, and b2 may be 0.

In Formula 2C, R₁to R₃may be each independently selected from a substituted or unsubstituted C₁-C₆₀alkyl group, a substituted or unsubstituted C₂-C₆₀alkenyl group, a substituted or unsubstituted C₂-C₆₀alkynyl group, a substituted or unsubstituted C₁-C₆₀alkoxy group, a substituted or unsubstituted C₃-C₁₀cycloalkyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀aryl group, a substituted or unsubstituted C₆-C₆₀aryloxy group, a substituted or unsubstituted C₆-C₆₀arylthio group, a substituted or unsubstituted C₁-C₆₀heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.

In an embodiment, in Formula 2C, R₁to R₃may be each independently selected from

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group;

In another embodiment, in Formula 2C, R₁to R₃may be each independently selected from

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group;

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

In some embodiments, in Formula 2C, R₁to R₃may be each independently selected from

In some embodiments, in Formula 2C, R₁to R₃may be each independently selected from —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, the group represented by Formulae 9-1 to 9-17, and the group represented by Formulae 10-1 to 10-18.

In an embodiment, in Formula 2C, R₁to R₃may be identical to each other.

In another embodiment, in Formula 2C, R₁and R₂are identical to each other and R₃is different from R₁; or R₁to R₃may be all different from one another.

In an embodiment, in Formula 2C, R₁to R₃may be all a methyl group, an ethyl group, or —CD₃.

In some embodiments, in Formula 2C, R₁and R₂may be a methyl group, and R₃may be a phenyl group.

In Formula 2B, when b1 is 1 or greater, at least one of R₁to R₃in Formula 2C may be optionally bound to a neighboring group Z₃to form a saturated or unsaturated ring having two to ten carbons (e.g., see Formulae 2B(4) to 2B(10)).

When b2 is 1 or greater, at least one of R₁to R₃in Formula 2C may be optionally bound to a neighboring group Z₄to form a saturated or unsaturated ring having two to ten carbons.

In some embodiments, in Formula 1, L₁may be selected from Formulae 3-1 to 3-110:

embedded image

In Formulae 3-1 to 3-110, Z₁and Z₂are the same as defined herein;

descriptions of Z_1aand Z_1bare each independently the same as defined in connection with Z₁;

descriptions of Z_2a, Z_2b, and Z_2ceach independently the same as defined in connection with Z₂;

aa2 and ab2 are each independently 1 or 2;

aa3 and ab3 are each independently an integer selected from 1 to 3;

aa4 and ab4 are each independently an integer selected from 1 to 4; and

* and *′ are each independently a binding site to M.

In some embodiments, in Formulae 3-1 to 3-110,

Z₁, Z₂, Z_1a, Z_1b, Z_2a, Z_2b, and Z_2cmay be each independently selected from

a C₁-C₂₀alkyl group and a C₁-C₂₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

—N(Q₁)(Q₂), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉),

wherein Q₁, Q₂and Q₆to Q₉are each independently selected from

aa2 and ab2 are each independently 1 or 2,

aa3 and ab3 are each independently an integer selected from 1 to 3,

aa4 and ab4 are each independently an integer selected from 1 to 4, and

* and *′ may be a binding site to M in Formula 1.

In some embodiments, in Formula 1, L₁may be selected from ligands represented by Formulae 3-1(1) to 3-1(59):

embedded image

In Formulae 3-1(1) to 3-1(59),

Z₁, Z₂, Z_1a, Z_1b, Z_1c, Z_1d, Z_2a, Z_2b, Z_2c, and Z_2dmay be each independently selected from a deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, the group represented by one of Formulae 9-1 to 9-17, and the group represented by one of Formulae 10-1 to 10-32.

In some embodiments, L₂of Formula 1 may be selected from ligands represented by Formulae 2B(1) to 2B(10):

embedded image

In Formulae 2B(1) to 2B(10), descriptions of Z₃, Z₄, a3, a4, and R₁to R₃are the same as defined herein, CY₄is selected from a benzene, a naphthalene, a carbazole, a dibenzofuran, and a dibenzothiophene, description of Z₅is the same as defined in connection with Z₃, and a5 is an integer selected from 1 to 6.

In some embodiments, L₂of Formula 1 may be selected from ligands represented by Formulae 2B-1 to 2B-60:

embedded image

In Formulae 2B-1 to 2B-60,

R₁to R₃may be each independently selected from

Z₃, Z_3a, Z_3b, Z₄, Z_4a, Z_4b, Z_4c, and Z_4dare each independently selected from

a deuterium, —F, a cyano group, a nitro group, —SF₅, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

—B(Q₆)(Q₇) and —P(═O)(Q₈)(Q₉),

wherein Q₆to Q₉are each independently selected from

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from a deuterium, a C₁-C₁₀alkyl group, and a phenyl group, but embodiments are not limited thereto.

In another embodiment, in Formulae 2B-1 to 2B-60,

R₁to R₃may be each independently selected from —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, the group represented by one of Formulae 9-1 to 9-17, and the group represented by one of Formulae 10-1 to 10-18,

Z₃, Z_3a, Z_3b, Z₄, Z_4a, Z_4b, Z_4c, and Z_4dmay be each independently selected from a deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, the group represented by one of Formulae 9-1 to 9-17, and the group represented by one of Formulae 10-1 to 10-32, but embodiments are not limited thereto.

In Formula 1, n1 and n2 are each independently 1 or 2, and n1+n2 is 2 or 3.

In some embodiments, M may be Ir, and n1+n2=3; or M may be Pt, and n1+n2=2, but embodiments are not limited thereto.

In another embodiment, in Formula 1, n2 may be 1.

The organometallic compound represented by Formula 1 does not have a form of a salt that is formed of an ion pair, and the organometallic compound may be neutral.

In an embodiment, in Formula 1,

M is Ir, and n1+n2=3; or M is Pt, and n1+n2=2,

L₁is a ligand represented by one of Formulae 3-1 and 3-110 (e.g., a ligand represented by one of Formula 3-1(1) to 3-1(59)),

L₂is a ligand represented by one of Formulae 2B(1) to 2B(10),

the organometallic compound represented by Formula 1 may be neutral, but embodiments are not limited thereto.

In another embodiment, in Formula 1,

M is Ir, and n1+n2=3; or M is Pt, and n1+n2=2,

L₁is a ligand represented by one of Formulae 3-1 and 3-110 (e.g., a ligand represented by one of Formula 3-1(1) to 3-1(59)),

L₂is a ligand represented by one of Formulae 2B-1 to 2B-60, and

the organometallic compound represented by Formula 1 may be neutral, but embodiments are not limited thereto.

The organometallic compound may be one of Compounds 1 to 109, but embodiments are not limited thereto:

embedded image

embedded image

In Formula 1, n1 and n2 may be 1 or 2. That is, n1 is not 0, and thus the organometallic compound represented by Formula 1 essentially includes the ligand represented by Formula 2A. Also, the ligand represented by Formula 2A is a N—C bidentate ligand that is linked to a metal M of Formula 1 through carbon and nitrogen. Thus, the organometallic compound represented by Formula 1 may have excellent thermal stability.

Also, the organometallic compound represented by Formula 1 has the ligand represented by Formula 2B, and the ligand represented by Formula 2B essentially has a group represented by Formula 2C as a substituent. The group represented by Formula 2C includes “Ge”, and thus an electric device, for example, an organic light-emitting device, including the organometallic compound represented by Formula 1 may have a high efficiency.

For example, the results of HOMO, LUMO, and triplet (Ti) energy levels of some compounds among the organometallic compounds evaluated by using a DFT method of Gaussian program (geometry optimized at the B3LYP, 6-31G(d,p) level) are shown in Table 1.

TABLE 1

Compound No.
HOMO (eV)
LUMO (eV)
T₁Energy level (eV)

1
−4.822
−1.242
2.567

2
−4.799
−1.160
2.623

3
−4.822
−1.242
2.567

4
−4.760
−1.142
2.644

5
−4.799
−1.160
2.623

6
−4.793
−1.156
2.622

Referring to Table 1, it may be confirmed that the compound is suitable to be used as a material for an organic light-emitting device.

A method of synthesizing the organometallic compound represented by Formula 1 may be understood to one of ordinary skill in the art by referring to Synthesis Examples used herein.

Therefore, the organometallic compound represented by Formula 1 is suitable as, for example, a dopant in an emission layer in an organic layer of an organic light-emitting device, and, according to another aspect of an embodiment, provided is an organic light-emitting device including:

a first electrode;

a second electrode; and

an organic layer disposed between the first electrode and the second electrode,

wherein the organic layer includes at least one of the organometallic compounds represented by Formula 1.

The organic light-emitting device includes the organic layer including the organometallic compound represented by Formula 1 and thus may have low driving voltage, high efficiency, high electrical power, high quantum efficiency, long lifespan, and excellent color purity.

The organometallic compound represented by Formula 1 may be used between a pair of electrodes in an organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included in the emission layer. Here, the organometallic compound serves as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host).

As used herein, the term “(organic layer) including at least one organometallic compound” denotes “(organic layer) including one of the organometallic compounds of Formula 1 above, or at least two different organometallic compounds of Formula 1 above.”

For example, the organic layer may include only Compound 1 as the organometallic compound. In this regard, Compound 1 may be included in the emission layer of the organic light-emitting device. Alternatively, the organic layer may include Compound 1 and Compound 2 as the organometallic compounds. In this regard, Compound 1 and Compound 2 may be included in the same layer (for example, both Compound 1 and Compound 2 may be included in the emission layer).

The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode. Alternatively, the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

For example, the first electrode may be an anode, the second electrode may be a cathode, and the organic layer may include:

i) a hole transport region disposed between the first electrode and the emission layer, wherein the hole transport region may include at least one selected from a hole injection layer, a hole transport layer, and an electron blocking layer; and

ii) an electron transport region disposed between the emission layer and the second electrode, wherein the electron transport region may include at least one selected from a hole blocking layer, an electron transport layer, and an electron injection layer.

As used herein, the term “organic layer” refers to a single and/or a plurality of layers disposed between the first electrode and the second electrode in an organic light-emitting device. The “organic layer” may include not only organic compounds but also organometallic complexes including metals.

FIG. 1 is a schematic view of an organic light-emitting device 10 according to an embodiment. Hereinafter, a structure and a method of manufacturing the organic light-emitting device according to an embodiment will be described with reference to FIG. 1. The organic light-emitting device 10 includes a first electrode 11, an organic layer 15, and a second electrode 19, which are sequentially layered in the stated order.

A substrate may be additionally disposed under the first electrode 11 or on the second electrode 19. The substrate may be a conventional substrate that is used in an organic light-emitting device, such as glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water repellency.

The first electrode 11 may be formed by vacuum-depositing or sputtering a material for forming the first electrode on the substrate. The first electrode 11 may be an anode. The material for the first electrode 11 may be selected from materials with a high work function for an easy hole injection. The first electrode 11 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. Examples of the material for the first electrode 11 may include indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO₂), and zinc oxide (ZnO). Alternatively, a metal such as magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag) may be used.

The first electrode 11 may have a single layer structure or a multi-layer structure including a plurality of layers. For example, the first electrode 11 may have a triple-layer structure of ITO/Ag/ITO, but embodiments are not limited thereto.

The organic layer 15 is disposed on the first electrode 11.

The organic layer 15 may include a hole transport region, an emission layer, and an electron transport region.

The hole transport region may be disposed between the first electrode 11 and the emission layer.

The hole transport region may include at least one of a hole injection layer, a hole transport layer, an electron blocking layer, and a buffer layer.

The hole transport region may only include a hole injection layer or a hole transport layer. Alternatively, the hole transport region may include a structure in which a hole injection layer/a hole transport layer or a hole injection layer/a hole transport layer/an electron blocking layer are sequentially layered on the first electrode 11.

When the hole transport region includes a hole injection layer, the hole injection layer (HIL) may be formed on the first electrode 11 by using various methods such as vacuum-deposition, spin coating, casting, and Langmuir-Blodgett (LB) method.

When the hole injection layer is formed using a vacuum deposition, vacuum deposition conditions may vary according to the compound that is used to form the hole injection layer, and the desired structure and thermal properties of the hole injection layer to be formed. For example, vacuum deposition may be performed at a temperature in a range of about 100° C. to about 500° C., a vacuum degree in a range of about 10⁻⁸torr to about 10⁻³torr, and a deposition rate in a range of about 0.01 Angstroms per second (Å/sec) to about 100 Å/sec. However, the deposition conditions are not limited thereto.

When the hole injection layer is formed using spin coating, the coating conditions may vary according to the compound that is used to form the hole injection layer, and the desired structure and thermal properties of the hole injection layer to be formed. For example, the coating rate may be in a range of about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a temperature at which heat treatment is performed to remove a solvent after coating may be in a range of about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

The conditions for forming a hole transport layer and an electron blocking layer may be inferred based on the conditions for forming the hole injection layer.

The hole transport region may include at least one selected from m-MTDATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, a spiro-TPD, a spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4′,4″-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (Pani/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (Pani/CSA), (polyaniline)/poly(4-styrenesulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below:

embedded image

In Formula 201, Ar₁₀₁and Ar₁₀₂may be each independently selected from

a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀alkyl group, a C₂-C₆₀alkenyl group, a C₂-C₆₀alkynyl group, a C₁-C₆₀alkoxy group, a C₃-C₁₀cycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₆₀aryl group, a C₆-C₆₀aryloxy group, a C₆-C₆₀arylthio group, a C₁-C₆₀heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

In Formula 201, xa and xb may be each independently an integer selected from 0 to 5, or 0, 1, or 2. For example, xa may be 1, and xb may be 0, but embodiments are not limited thereto.

In Formulae 201 and 202, R₁₀₁to R₁₀₈, R₁₁₁to R₁₁₉, and R₁₂₁to R₁₂₄may be each independently selected from

a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀alkyl group (e.g., a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, or a hexyl group), and a C₁-C₁₀alkoxy group (e.g., a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentoxy group);

a C₁-C₁₀alkyl group and a C₁-C₁₀alkoxy group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, and a phosphoric acid group or a salt thereof;

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group; and

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀alkyl group, and a C₁-C₁₀alkoxy group, but embodiments are not limited thereto.

In Formula 201, R₁₀₉may be selected from

a phenyl group, a naphthyl group, an anthracenyl group and a pyridinyl group; and

a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀alkyl group, a C₁-C₂₀alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, but embodiments are not limited thereto.

In an embodiment, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments are not limited thereto:

embedded image

In Formula 201A, descriptions of R₁₀₁, R₁₁₁, R₁₁₂, and R₁₀₉are the same as provided herein.

For example, the compound represented by Formula 201 and the compound represented by Formula 202 may include Compounds HT1 to HT20, but they are not limited thereto:

embedded image

A thickness of the hole transport region may be in a range of about 100 Angstroms (Å) to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes a hole injection layer and a hole transport layer, the thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, and for example, about 100 Å to about 1,000 Å, and the thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, and for example, about 100 Å to about 1,500 Å. When the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, excellent hole transport characteristics may be obtained without a substantial increase in driving voltage.

The hole transport region may further include, in addition to the mentioned materials above, a charge-generating material to improve conductive properties. The charge-generating material may be homogeneously or non-homogeneously dispersed throughout the hole transport region.

The charge-generating material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone derivative, a metal oxide, and a cyano group-containing compound, but embodiments are not limited thereto. For example, non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonedimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonedimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenum oxide; and a compound containing a cyano group, such as Compound HT-D1 illustrated below, but they are not limited thereto.

embedded image

The hole transport region may further include a buffer layer.

The buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus may increase efficiency.

The emission layer may be formed on the hole transport region by using various methods, such as vacuum-deposition, spin coating, casting, or an LB method. When the emission layer is formed by vacuum-deposition or spin coating, vacuum-deposition and coating conditions for the emission layer may be generally similar to the conditions for forming a hole injection layer, though the conditions may vary depending on the compound used.

When the hole transport region include an electron blocking layer, a material for the electron blocking layer may be selected from a material that may be used in the hole transport region and a material for a host, but embodiments are not limited thereto. For example, when the hole transport region includes the electron blocking layer, the material for the electron blocking layer may be mCP.

The emission layer may include a host and a dopant, and the dopant includes the organometallic compound represented by Formula 1.

The host may include at least one of TPBi, TBADN, ADN (also, referred to as “DNA”), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:

embedded image

Alternatively, the host may further include a compound represented by Formula 301:

embedded image

In Formula 301, Ar₁₁₁and Ar₁₁₂may be each independently selected from

a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group; and

a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

In Formula 301, Ar₁₁₃to Ar₁₁₆may be each independently selected from

a C₁-C₁₀alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group; and

a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

In Formula 301, g, h, i, and j may be each independently an integer selected from 0 to 4, for example, 0, 1, or 2.

In Formula 301, Ar₁₁₃to Ar₁₁₆may be each independently selected from

a C₁-C₁₀alkyl group substituted with at least one of a phenyl group, a naphthyl group, and an anthracenyl group;

a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group;

a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀alkyl group, a C₂-C₆₀alkenyl group, a C₂-C₆₀alkynyl group, a C₁-C₆₀alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group; and

embedded image

but embodiments are not limited thereto.

Alternatively, the host may include a compound represented by Formula 302:

embedded image

In Formula 302, descriptions of Ar₁₂₂to Ar₁₂₅are the same as defined in connection with Ar₁₁₃of Formula 301.

In Formula 302, Ar₁₂₆and Ar₁₂₇may be each independently a C₁-C₁₀alkyl group (e.g., a methyl group, an ethyl group, or a propyl group).

In Formula 302, k and l may be each independently an integer selected from 0 to 4. For example, k and l may be 0, 1, or 2.

The compound represented by Formula 301 and the compound represented by Formula 302 may include Compounds H1 to H42, but embodiments are not limited thereto:

embedded image

When the organic light-emitting device is a full color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. Alternatively, the emission layer may have a structure in which the red emission layer, the green emission layer, and/or the blue emission layer are layered to emit white light or other various embodiments are possible.

When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts to about 15 parts by weight based on 100 parts by weight of the host, but embodiments are not limited thereto.

A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. When the thickness of the emission layer is within this range, excellent light-emission characteristics may be obtained without a substantial increase in driving voltage.

Then, an electron transport region may be disposed on the emission layer.

The electron transport region may include at least one selected from a hole blocking layer, an electron transport layer, and an electron injection layer, but is not limited thereto.

For example, the electron transport region may have a structure of a hole blocking layer/an electron transport layer/an electron injection layer or an electron transport layer/an electron injection layer, but it is not limited thereto. The electron transport layer may have a single layer structure or a multi-layer structure including two or more different materials.

The conditions for forming a hole blocking layer, an electron transport layer, and an electron injection layer may be inferred based on the conditions for forming the hole injection layer.

When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen and Balq, but embodiments are not limited thereto:

embedded image

A thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. When the thickness of the hole blocking layer is within this range, excellent hole blocking characteristics may be obtained without a substantial increase in driving voltage.

The electron transport layer may further include at least one of BCP and Bphen above and Alq₃, Balq, TAZ, and NTAZ below:

embedded image

Alternatively, the electron transport layer may include at least one selected from Compounds ET1 and ET2, but it is not limited thereto.

embedded image

A thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. When the thickness of the electron transport layer is within this range, excellent electron transport characteristics may be obtained without a substantial increase in driving voltage.

The electron transport layer may further include a metal-containing material in addition to the materials described above.

The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium quinolate, LiQ) or ET-D2.

embedded image

The electron transport region may include an electron injection layer (EIL) that facilitates electron injection from the second electrode 19.

The electron injection layer may include at least one selected from LiF, NaCl, CsF, Li₂O, and BaO.

A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. When the thickness of the electron injection layer is within this range, excellent electron injection characteristics may be obtained without a substantial increase in driving voltage.

The second electrode 19 is disposed on the organic layer 15. The second electrode 19 may be a cathode. A material for the second electrode 19 may be a material having a relatively low work function, such as a metal, an alloy, an electrically conductive compound, and a mixture thereof. Detailed examples of the material for forming the second electrode 19 are lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag). Alternatively, ITO or IZO may be used to form a transmissive second electrode 19 to manufacture a top emission light-emitting device, and such a variation may be possible.

Hereinbefore, the organic light-emitting device has been described with reference to FIG. 1, but embodiments are not limited thereto.

A C₁-C₆₀alkyl group as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms. Detailed examples thereof are a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. A C₁-C₆₀alkylene group as used herein refers to a divalent group having the same structure as a C₁-C₆₀alkyl group.

A C₁-C₆₀alkoxy group as used herein refers to a monovalent group represented by —OA₁₀₁(wherein A₁₀₁is the C₁-C₆₀alkyl group). Detailed examples thereof are a methoxy group, an ethoxy group, and an isopropyloxy group.

A C₂-C₆₀alkenyl group as used herein refers to a hydrocarbon aliphatic group formed by including at least one carbon-carbon double bond in the middle or at the terminal of the C₂-C₆₀alkyl group as defined above. Detailed examples thereof are an ethenyl group, a propenyl group, and a butenyl group. A C₂-C₆₀alkenylene group as used herein refers to a divalent group having the same structure as a C₂-C₆₀alkenyl group.

A C₂-C₆₀alkynyl group as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon triple bond in the middle or at the terminal of the C₂-C₆₀alkyl group as defined above. Detailed examples thereof are an ethynyl group and a propynyl group. A C₂-C₆₀alkynylene group as used herein refers to a divalent group having the same structure as a C₂-C₆₀alkynyl group.

A C₃-C₁₀cycloalkyl group as used herein refers to a monovalent monocyclic saturated hydrocarbon group including 3 to 10 carbon atoms. Detailed examples thereof are a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. A C₃-C₁₀cycloalkylene group as used herein refers to a divalent group having the same structure as a C₃-C₁₀cycloalkyl group.

A C₁-C₁₀heterocycloalkyl group as used herein refers to a monovalent monocyclic saturated group including at least one hetero atom selected from N, O, P, and S as a ring-forming atom and 1 to 10 carbon atoms. Detailed examples thereof are a tetrahydrofuranyl group and a tetrahydrothiophenyl group. A C₁-C₁₀heterocycloalkylene group as used herein refers to a divalent group having the same structure as a C₁-C₁₀heterocycloalkyl group.

A C₃-C₁₀cycloalkenyl group as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms and at least one double bond in its ring, and which is not aromatic. Detailed examples thereof are a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. A C₃-C₁₀cycloalkenylene group as used herein refers to a divalent group having the same structure as a C₃-C₁₀cycloalkenyl group.

A C₁-C₁₀heterocycloalkenyl group as used herein refers to a monovalent monocyclic group including at least one hetero atom selected from N, O, P, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one double bond in its ring. Detailed examples of the C₁-C₁₀heterocycloalkenyl group are a 2,3-dihydrofuranyl group and a 2,3-dihydrothiophenyl group. A C₁-C₁₀heterocycloalkenylene group as used herein refers to a divalent group having the same structure as a C₁-C₁₀heterocycloalkenyl group.

A C₆-C₆₀aryl group as used herein refers to a monovalent group including a carbocyclic aromatic system having 6 to 60 carbon atoms, and a C₆-C₆₀arylene group as used herein refers to a divalent group including a carbocyclic aromatic system having 6 to 60 carbon atoms. Detailed examples of the C₆-C₆₀aryl group are a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C₆-C₆₀aryl group and the C₆-C₆₀arylene group each include two or more rings, the rings may be fused to each other.

A C₁-C₆₀heteroaryl group used herein refers to a monovalent group having an aromatic system including at least one hetero atom selected from N, O, P, and S as a ring-forming atom and 1 to 60 carbon atoms. A C₁-C₆₀heteroarylene group as used herein refers to a divalent group having a carbocyclic aromatic system including at least one hetero atom selected from N, O, P, and S as a ring-forming atom and 1 to 60 carbon atoms. Detailed examples of the C₁-C₆₀heteroaryl group are a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C₁-C₆₀heteroaryl group and the C₁-C₆₀heteroarylene group each include a plurality of rings, the rings may be fused to each other.

A C₆-C₆₀aryloxy group as used herein indicates —OA₁₀₂(wherein A₁₀₂is the C₆-C₆₀aryl group), and a C₆-C₆₀arylthio group as used herein indicates —SA₁₀₃(wherein A₁₀₃is the C₆-C₆₀aryl group).

A monovalent non-aromatic condensed polycyclic group as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) that has two or more rings condensed to each other, only carbon atoms as ring forming atoms, wherein the molecular structure as a whole is non-aromatic in the entire molecular structure. A detailed example of the monovalent non-aromatic condensed polycyclic group is a fluorenyl group. A divalent non-aromatic condensed polycyclic group as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

A monovalent non-aromatic condensed heteropolycyclic group as used herein refers to a monovalent group (for example, having 1 to 60 carbon atoms) that has two or more rings condensed to each other, has a hetero atom selected from N, O, P, and S, other than carbon atoms, as a ring forming atom, wherein the molecular structure as a whole is non-aromatic in the entire molecular structure. The monovalent non-aromatic condensed heteropolycyclic group includes a carbazolyl group. A divalent non-aromatic condensed hetero-polycyclic group as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed hetero-polycyclic group.

At least one of substituents of the substituted C₁-C₆₀alkyl group, substituted C₂-C₆₀alkenyl group, substituted C₂-C₆₀alkynyl group, substituted C₁-C₆₀alkoxy group, substituted C₃-C₁₀cycloalkyl group, substituted C₁-C₁₀heterocycloalkyl group, substituted C₃-C₁₀cycloalkenyl group, substituted C₁-C₁₀heterocycloalkenyl group, substituted C₆-C₆₀aryl group, substituted C₆-C₆₀aryloxy group, substituted C₆-C₆₀arylthio group, substituted C₁-C₆₀heteroaryl group, substituted monovalent non-aromatic condensed polycyclic group, and substituted monovalent non-aromatic condensed heteropolycyclic group is selected from

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(═O)(Q₃₈)(Q₃₉),

wherein Q₁, Q₂, Q₆to Q₉, Q₁₁to Q₁₉, Q₂₁to Q₂₉, and Q₃₁to Q₃₉are each independently selected from a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀alkyl group, a substituted or unsubstituted C₂-C₆₀alkenyl group, a substituted or unsubstituted C₂-C₆₀alkynyl group, a substituted or unsubstituted C₁-C₆₀alkoxy group, a substituted or unsubstituted C₃-C₁₀cycloalkyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀aryl group, a substituted or unsubstituted C₆-C₆₀aryloxy group, a substituted or unsubstituted C₆-C₆₀arylthio group, a substituted or unsubstituted C₁-C₆₀heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group (for example, a hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀alkyl group, a C₂-C₆₀alkenyl group, a C₂-C₆₀alkynyl group, a C₁-C₆₀alkoxy group, a C₃-C₁₀cycloalkyl group, a C₁-C₁₀heterocycloalkyl group, a C₃-C₁₀cycloalkenyl group, a C₁-C₁₀heterocycloalkenyl group, a C₆-C₆₀aryl group, a C₆-C₆₀aryl group substituted with a C₁-C₆₀alkyl group or a C₆-C₆₀aryl group, a C₆-C₆₀aryloxy group, a C₆-C₆₀arylthio group, a C₁-C₆₀heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group).

The present inventive concept will be described in further detail with reference to the following examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present inventive concept.

Hereinafter, the compound according to an embodiment and an organic light-emitting device will be described in detail by referring to Synthesis Examples and Examples, but embodiments are not limited thereto. The wording “B was used instead of A” used in describing Synthesis Examples means that an amount of B used was identical to an amount of A used based on molar equivalence.

EXAMPLE
Synthesis Example 1 Synthesis of Compound 2
Synthesis of Compound A2

embedded image

10.0 grams (g) (42.22 millimoles (mmol)) of 2,5-dibromopyridine was added to 200 milliliters (ml) of diethyl ether. The mixture was cooled to −78° C., 42.22 mmol of n-BuLi was slowly added thereto, and the resulting mixture was stirred for 1 hour at a temperature of −78° C. Then, 5.2 ml (42.22 mmol) of chloro(trimethyl)germane was added thereto, and the mixture was reacted for 1 hour at a temperature of −78° C., heated to room temperature, and then allowed to stir for 12 hours. The resultant was extracted with dichloromethane. The organic layer was dried using anhydrous magnesium sulfate and filtered. The solvent was removed from the resultant under reduced pressure, and the residue thus obtained was purified by column chromatography with ethyl acetate:hexane=1:15 as an eluent to obtain 6.3 g of Compound A2 (yield: 54%). The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 8.36 (s, 1H), 7.58 (d, 1H), 7.44 (d, 2H), 0.42 (s, 9H)

MS: m/z 275.94 [(M+1)⁺]

Synthesis of Compound A1

embedded image

6.30 g (22.93 mmol) of Compound A2, 5.35 g (43.85 mmol) of biphenylboronic acid, 0.90 g (3.99 mmol) of Pd(PPh₃)₄, and 2.09 g (7.97 mmol) of K₂CO₃were mixed with 100 ml of toluene and 50 ml of distilled water, and the mixture was stirred for 18 hours at 70° C., cooled to room temperature, and filtered. The resultant was extracted with dichloromethane. The organic layer, was dried using anhydrous magnesium sulfate (MgSO₄) and filtered. The solvent was removed from the resultant under reduced pressure, and the residue thus obtained was purified by column chromatography with ethyl acetate:hexane=1:25 to obtain 5.1 g of Compound A1 (yield: 64%). The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 8.75 (s, 1H), 8.23 (s, 1H), 7.96 (d, 1H), 7.84 (dd, 1H), 7.75 (d, 1H), 7.65 (t, 3H), 7.54 (t, 1H), 7.45 (t, 2H), 7.38 (t, 1H), 0.46 (s, 9H)

MS: m/z 349.09 [(M+1)⁺]

Synthesis of Compound M2A

embedded image

10.0 g (64.43 mmol) of 2-phenylpyridine and 10.1 g (28.64 mmol) of iridium chloride trihydrate were mixed with 150 ml of ethoxyethanol and 50 ml of distilled water, and the mixture was stirred under reflux for 24 hours to allow a reaction to proceed. The mixture was cooled to room temperature. The solid thus obtained was filtered and separated, thoroughly washed with water, methanol, and hexane in the stated order. Then, the solid was dried in a vacuum oven to obtain 13.8 g of Compound M2A (yield: 90%).

Synthesis of Compound M1A

embedded image

2.36 g (2.20 mmol) of Compound M2A was mixed with 60 ml of methylene chloride (MC), and then 1.13 g (4.40 mmol) of AgOTf was dissolved in 20 ml of a mixture of dichloromethane/methanol (3:1). Then, the flask was wrapped with aluminum foil to protect the contents from the action of light, and the mixture was stirred for 18 hours at room temperature. The solid thus produced was removed by using a celite filter. The solvent was removed from the resultant under reduced pressure. The solid (Compound M1A) thus obtained was used in the next step without additional purification.

Synthesis of Compound 2

embedded image

3.06 g (4.29 mmol) of Compound M1A and 1.79 g (5.15 mmol) of Compound A1 was mixed with 20 ml of ethanol, and the mixture was stirred under reflux for 15 hours to allow the reaction to proceed, and cooled to room temperature. A solid obtained by filtering the mixture was thoroughly washed with ethanol and hexane, and the resultant was purified by column chromatography with ethyl acetate:hexane=1:6 as an eluent to obtain 2.1 g of Compound 2 (yield: 58%). The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 7.89 (m, 4H), 7.61 (m, 8H), 7.50 (d, 1H), 7.40 (m, 3H), 7.24 (m, 1H), 7.13 (d, 1H), 6.89 (m, 9H), 0.19 (s, 9H)

MS: m/z 849.18 [(M+1)⁺]

Synthesis Example 2 Synthesis of Compound 7
Synthesis of Compound B3

embedded image

20.0 g (79.71 mmol) of 2,5-dibromo-4-methylpyridine, 11.7 g (95.65 mmol) of phenylboronic acid, 0.90 g (3.99 mmol) of Pd(OAc)₂, 2.09 g (7.97 mmol) of PPh₃, and 22.0 g (159.4 mmol) of K₂CO₃were mixed with 200 ml of acetonitrile and 100 ml of methanol, and the mixture as stirred at 50° C. for 18 hours, cooled to room temperature, and filtered. The resultant was extracted with dichloromethane to collect an organic layer, which was then dried using anhydrous magnesium sulfate (MgSO₄) and filtered. The solvent was removed from the resultant under reduced pressure, and the residue thus obtained was purified by column chromatography with ethyl acetate:hexane=1:25 as an eluent to obtain 9.6 g of Compound B3 (yield: 48%).

Synthesis of Compound B2

embedded image

9.1 g of Compound B2 (yield: 82%) was obtained in the same manner as in the synthesis of Compound A2 of Synthesis Example 1, except that 9.6 g (38.61 mmol) of Compound B3 was used instead of 2,5-dibromopyridine. The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 8.53 (s, 1H), 7.92 (d, 2H), 7.39 (m, 4H), 2.40 (s, 3H), 0.44 (s, 9H)

MS: m/z 287.07 [(M+1)⁺]

Synthesis of Compound 7

embedded image

1.3 g of Compound 7 (yield: 33%) was obtained in the same manner as in the synthesis of Compound 2 of Synthesis Example 1, except that 1.7 g (6.11 mmol) of Compound B2 instead of Compound A1 and 3.6 g (5.09 mmol) of Compound M1A were used. The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 7.91 (m, 4H), 7.65 (m, 8H), 7.54 (s, 1H), 7.40 (m, 4H), 7.24 (s, 1H), 7.13 (d, 2H), 6.89 (m, 2H), 2.43 (s, 3H), 0.20 (s, 9H)

MS: m/z 787.16 [(M+1)⁺]

Synthesis Example 3 Synthesis of Compound 8
Synthesis of Compound B1

embedded image

2.30 g (8.04 mmol) of Compound B2 was mixed with 40 ml of THF and cooled to −78° C. Then, 7.24 ml (14.48 mmol) of lithium diisopropylamide (LDA) was slowly added thereto. The mixture was stirred at −78° C. for 1 hour to allow the reaction to proceed, then warmed to room temperature, and stirred at room temperature for additional 1.5 hour. Then, the temperature of the resultant mixture was lowered to −78° C., 1.25 mL (13.27 mmol) of 2-bromopropane was slowly added thereto, and the mixture was warmed to room temperature, at which the reaction was allowed to stir for 12 hours. The resultant was extracted with dichloromethane to collect an organic layer, which was then dried using anhydrous magnesium sulfate (MgSO₄) and filtered. The solvent was removed from the resultant under reduced pressure, and the residue thus obtained was purified by column chromatography with ethyl acetate:hexane=4:96 as an eluent to obtain 2.0 g of Compound B1 (yield: 76%). The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 8.55 (s, 1H), 7.89 (d, 2H), 7.40 (m, 4H), 3.25 (d, 2H), 1.85 (m, 1H), 0.90 (d, 6H), 0.45 (s, 9H)

MS: m/z 329.12 [(M+1)⁺]

Synthesis of Compound 8

embedded image

1.0 g of Compound 8 (yield: 27%) was obtained in the same manner as in the synthesis of Compound 2 in Synthesis Example 1, except that 1.7 g (5.26 mmol) of Compound B1 instead of Compound B2 and 3.1 g (4.39 mmol) of Compound M1A were used. The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 7.89 (m, 4H), 7.63 (m, 8H), 7.53 (s, 1H), 7.39 (m, 4H), 7.25 (s, 1H), 7.15 (d, 2H), 6.90 (m, 2H), 3.31 (d, 2H), 1.89 (m, 1H), 0.91 (d, 6H), 0.18 (s, 9H)

MS: m/z 829.20 [(M+1)⁺]

Synthesis Example 4 Synthesis of Compound 10
Synthesis of Compound C3

embedded image

9.5 g of Compound C3 (yield: 78%) was obtained in the same manner as in the synthesis of Compound B3 in Synthesis Example 2, except that 8.0 g (40.34 mmol) of ([1,1′-biphenyl]-3-yl)boronic acid was used instead of phenylboronic acid.

Synthesis of Compound C2

embedded image

2.5 g of Compound C2 (yield: 76%) was obtained in the same manner as in the synthesis of Compound A2 in Synthesis Example 1, except that 3.0 g (9.25 mmol) of Compound C3 was used instead of 2,5-dibromopyridine.

Synthesis of Compound C1

embedded image

2.1 g of Compound C1 (yield: 75%) was obtained in the same manner as in the synthesis of Compound B1 in Synthesis Example 3, except that 2.5 g (7.03 mmol) of Compound C2 was used instead of Compound B2.

Synthesis of Compound 10

embedded image

1.2 g of Compound 10 (yield: 34%) was obtained in the same manner as in the synthesis of Compound 2 in Synthesis Example 1, except that 1.9 g (4.65 mmol) of Compound C1 instead of Compound A1 and 2.8 g (3.87 mmol) of Compound M1A were used. The compound was identified using LCMS and ¹H NMR.

¹H-NMR (CDCl₃) δ 7.89 (m, 4H), 7.59 (m, 8H), 7.49 (d, 1H), 7.38 (m, 3H), 7.21 (m, 1H), 7.12 (d, 1H), 6.87 (m, 8H), 3.30 (d, 2H), 1.88 (m, 1H), 0.90 (d, 6H), 0.19 (s, 9H)

MS: m/z 905.23 [(M+1)⁺]

Example 1

An ITO glass substrate (an anode) was cut to a size of 50 millimeters (mm)×50 mm×0.5 mm, and then ultrasonicated in acetone, isopropyl alcohol, and pure water (for 15 minutes in each solvent), and then cleaned by UV ozone for 30 minutes.

Then, m-MTDATA was deposited on the glass substrate at a deposition rate of 1 Angstrom per second (Å/sec) to form a hole injection layer having a thickness of 600 Angstroms (Å) on the ITO electrode (anode), and α-NPD was deposited on the hole injection layer at a deposition rate of 1 Å/sec to form a hole transport layer having a thickness of 250 Å.

Compound 2 (a dopant) and CBP (a host) were co-deposited on the hole transport layer at deposition rates of 0.1 Å/sec and 1 Å/sec, respectively, to form an emission layer having a thickness of 400 Å.

BAlq was deposited on the emission layer to form a hole blocking layer having a thickness of 50 Å, Alq₃was deposited on the hole blocking layer to form an electron transport layer having a thickness of 300 Å, LiF was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å, and Al was deposited on the electron injection layer to form a second electrode (a cathode) having a thickness of 1,200 Å, thereby manufacturing an organic light-emitting device having a structure of ITO/m-MTDATA (600 Å)/α-NPD (250 Å)/CBP+10% (Compound 2) (400 Å)/Balq (50 Å)/Alq₃(300 Å)/LiF (10 Å)/Al (1200 Å).

Examples 2 to 4 and Comparative Examples 1 to 3

Organic light-emitting devices were manufactured in the same manner as in Example 1, except that Compounds shown in Table 2 were each used instead of Compound 2 as a dopant in the formation of the emission layer.

Evaluation Example 1: Evaluation of Organic Light-Emitting Device Characteristics

Driving voltage, efficiency, color purity, maximum efficiency, FWHM of EL spectrum, maximum emission wavelengths of the organic light-emitting devices manufactured in Examples 1 to 4 and Comparative Examples 1 to 3 were measured, and the results are shown in Table 2. The measurement was performed by using a current-voltmeter (available from Keithley 2400) and a luminance meter (available from Minolta Cs-1000A).

TABLE 2

Efficiency

Maximum

Driving
(Cd/A)
CIE x
Maximum

emission

voltage
(at driving
(at driving
efficiency
FWHM
wavelength

Dopant
(V)
voltage)
voltage)
(Cd/A)
(nm)
(nm)

Example 1
Compound 2
4.9
49.6
0.354
59.0
74.6
523

Example 2
Compound 7
4.9
49.3
0.330
60.5
75.9
517

Example 3
Compound 8
5.0
47.5
0.325
62.0
77
515

Example 4
Compound 10
4.9
50.0
0.322
60.0
79
518

Comparative
Compound R1
5.4
49.2
0.374
57.7
81.8
528

Example 1

Comparative
Compound R2
5.2
42.0
0.331
55.0
77
520

Example 2

Comparative
Compound R3
5.4
39.0
0.315
46.5
84
513

Example 3

embedded image

Referring to Table 2, a coordinate of CIE x of the organic light-emitting devices prepared in Examples 1 to 4 was in a range of 0.322 to 0.354, but a coordinate of CIE x of the organic light-emitting device prepared in Comparative Example 1 was 0.374. Thus, it was confirmed that the organic light-emitting devices of Examples 1 to 4 had better color purities than that of the organic light-emitting device of Comparative Example 1. Also, it may be confirmed that efficiencies and maximum efficiencies of the organic light-emitting devices of Examples 1 to 4 are better than those of organic light-emitting devices of Comparative Examples 2 and 3.

As described above, according to the one or more of the above exemplary embodiments, the organometallic compound has excellent electric characteristics and thermal stability. Thus, an organic light-emitting device including the organometallic compound may have low driving voltage, high efficiency, and excellent color purity.

It should be understood that the exemplary embodiments described therein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each exemplary embodiment should typically be considered as available for other similar features or aspects in other exemplary embodiments.

While one or more exemplary embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope as defined by the following claims.

Claims

1. An organometallic compound represented by Formula 1:
2. The organometallic compound of claim 1, wherein in Formula 2A and 2B(5) to 2B(10), CY1 and CY3 are each independently selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a quinoline ring, an isoquinoline ring, a quinazoline ring, a quinoxaline ring, a triazole ring, an imidazole ring, and a pyrazole ring, andCY2 and CY4 are each independently selected from a benzene ring, a naphthalene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a quinoline ring, an isoquinoline ring, a quinazoline ring, a quinoxaline ring, a carbazole ring, a dibenzofuran ring, and a dibenzothiophene ring.
3. The organometallic compound of claim 1, wherein in Formula 2A and 2B(5) to 2B(10), CY1 is selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a triazole ring, an imidazole ring, and a pyrazole ring, andCY2 and CY4 are each independently selected from a benzene ring, a naphthalene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a carbazole ring, a dibenzofuran ring, and a dibenzothiophene ring.
4. The organometallic compound of claim 1, wherein in Formula 2A and 2B(5) to 2B(10), Z1 to Z5 are each independently selected froma hydrogen, a deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF5, a C1-C20 alkyl group, and a C1-C20 alkoxy group;a C1-C20 alkyl group and a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —C, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group; and—B(Q6)(Q7) and —P(═O)(Q8)(Q),wherein Q to Q are each independently selected from—CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, and —CD2CDH2;an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; andan n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from a deuterium, a C1-C10 alkyl group, and a phenyl group.
5. The organometallic compound of claim 1, wherein in Formula 2A and 2B(5) to 2B(10), Z1 to Z5 are each independently selected froma hydrogen, a deuterium, —F, a cyano group, a nitro group, —SF5, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a cyano group, a nitro group, a C1-C10 alkyl group, C1-C10 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group; and—B(Q6)(Q7) and —P(═O)(Q8)(Q),wherein Q to Q are each independently selected from—CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, and —CD2CDH2;an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; andan n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from a deuterium, a C1-C10 alkyl group, and a phenyl group.
6. The organometallic compound of claim 1, wherein in Formula 2A and 2B(5) to 2B(10), Z1 to Z5 are each independently selected from a hydrogen, a deuterium, —F, a cyano group, a nitro group, —SF5, —CH3, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a group represented by Formulae 9-1 to 9-17, and a group represented by Formulae 10-1 to 10-32:
7. The organometallic compound of claim 1, R2 and R3 are each independently selected from a C1-C20 alkyl group and a C1-C20 alkoxy group;a C1-C20 alkyl group and a C1-C20 alkoxy group, each substituted with at least one selected from a deuterium, —F, —C, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group; anda cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group.
8. The organometallic compound of claim 1, R2 and R3 are each independently selected froma methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group; anda methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group, each substituted with at least one selected from a deuterium, —F, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a cyano group, a nitro group, a C1-C10 alkyl group, a C1-C10 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group.
9. The organometallic compound of claim 1, R2 and R3 are each independently selected from —CH3, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a group represented by Formulae 9-1 to 9-17, and a group represented by Formulae 10-1 to 10-18:
10. The organometallic compound of claim 1, R2 and R3 are identical to one another.
11. The organometallic compound of claim 1, wherein in Formula 1, L1 is selected from Formulae 3-1 to 3-110:
12. The organometallic compound of claim 1, wherein in Formula 1, L1 is selected from ligands represented by Formulae 3-1(1) to 3-1(59):
13. The organometallic compound of claim 1, wherein in Formula 1, M is Ir and the sum of n1 and n2 is 3, orM is Pt and the sum of n1 and n2 is 2,wherein the organometallic compound does not comprise an ionic pair.
14. An organic light-emitting device comprising: a first electrode;a second electrode; andan organic layer disposed between the first electrode and the second electrode,wherein the organic layer comprises an emission layer, andwherein the organic layer comprises at least one organometallic compound of claim 1.
15. The organic light-emitting device of claim 14, wherein the emission layer comprises the organometallic compound of claim 1, wherein the emission layer further comprises a host, and wherein an amount of the organometallic compound is less than an amount of the host.

Priority Claims (1)

Number	Date	Country	Kind
10-2014-0182552	Dec 2014	KR	national

US Referenced Citations (21)

Number	Name	Date	Kind
8492006	Ma et al.	Jul 2013	B2
9217004	Ma et al.	Dec 2015	B2
9478756	Lee et al.	Oct 2016	B2
9490437	Hwang	Nov 2016	B2
9512355	Ma et al.	Dec 2016	B2
9911924	Kim	Mar 2018	B2
10003035	Hwang	Jun 2018	B2
10135009	Hwang	Nov 2018	B2
20080074033	Ionkin	Mar 2008	A1
20090108737	Kwong	Apr 2009	A1
20110050093	Fukuzaki	Mar 2011	A1
20110227049	Xia	Sep 2011	A1
20120217868	Ma et al.	Aug 2012	A1
20130146848	Ma et al.	Jun 2013	A1
20130334521	Lee	Dec 2013	A1
20150090974	Kim	Apr 2015	A1
20160111644	Cho	Apr 2016	A1
20160111663	Kim	Apr 2016	A1
20160111664	Ito	Apr 2016	A1
20160111665	Kim	Apr 2016	A1
20160268519	Choi	Sep 2016	A1

Foreign Referenced Citations (11)

Number	Date	Country
2005327526	Nov 2005	JP
2013107886	Jun 2013	JP
2013121957	Jun 2013	JP
2014508764	Apr 2014	JP
2014509587	Apr 2014	JP
1020120114030	Oct 2012	KR
1020130065595	Jun 2013	KR
20130110934	Oct 2013	KR
WO-2012098996	Jul 2012	WO
WO-2014007565	Jan 2014	WO
WO-2014196685	Dec 2014	WO

Non-Patent Literature Citations (3)

Entry
Machine Translation of KR-20130110934-A.
Extended Search Report issued by the European Patent Office dated Apr. 22, 2016.
Office Action issued by the Japanese Patent Office dated Jul. 23, 2019 in the examination of the Japanese Patent Application No. 2015-244997, which corresponds to U.S. Appl. No. 14/967,594, with English translation.

Related Publications (1)

	Number	Date	Country
	20160181530 A1	Jun 2016	US

Organometallic compound and organic light-emitting device including the same

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Disclaimer

Term Extension

Abstract

Description

Claims

Priority Claims (1)

US Referenced Citations (21)

Foreign Referenced Citations (11)

Non-Patent Literature Citations (3)

Related Publications (1)